Amgen announces strategy to use its emerging drug pipeline to offset upcoming patent expirations and target growth by 2026. The plan aims to preserve revenue streams and market position amid intense competition in the biotech sector. Amgen leadership, investors, and regulatory agencies overseeing drug approvals. Upcoming clinical trial readouts and regulatory filings for pipeline candidates, plus potential partnership announcements. Amgen has identified growth opportunities in its drug pipeline to counter the impending patent expirations impacting its revenue. By focusing on innovative treatments, the company aims to sustain its market position and financial performance despite competitive pressures in the healthcare sector.
INTELLIGENCE
Social Pulse
AI estimate · not scraped